Literature DB >> 31839873

Using Adaptive Designs to Avoid Selecting the Wrong Arms in Multiarm Comparative Effectiveness Trials.

Byron J Gajewski1, Jeffrey Statland2, Richard Barohn2.   

Abstract

Limited resources are a challenge when planning comparative effectiveness studies of multiple promising treatments, often prompting study planners to reduce the sample size to meet the financial constraints. The practical solution is often to increase the efficiency of this sample size by selecting a pair of treatments among the pool of promising treatments before the clinical trial begins. The problem with this approach is that the investigator may inadvertently leave out the most beneficial treatment. This paper demonstrates a possible solution to this problem by using Bayesian adaptive designs. We use a planned comparative effectiveness clinical trial of treatments for sialorrhea in amyotrophic lateral sclerosis as an example of the approach. Rather than having to guess at the two best treatments to compare based on limited data, we suggest putting more arms in the trial and letting response adaptive randomization (RAR) determine better arms. To ground this study relative to previous literature we first compare RAR, adaptive equal randomization (ER), arm(s) dropping, and a fixed design. Given the goals of this trial we demonstrate that we may avoid 'type III errors' - inadvertently leaving out the best treatment - with little loss in power compared to a two-arm design, even when choosing the correct two arms for the two-armed design. There are appreciable gains in power when the two arms are prescreened at random.

Entities:  

Keywords:  Bayesian methods; Response adaptive randomization; adaptive designs; clinical trials; equal randomization

Year:  2019        PMID: 31839873      PMCID: PMC6909934          DOI: 10.1080/19466315.2019.1610044

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.452


  28 in total

1.  Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot.

Authors:  Byron J Gajewski; Scott M Berry; Melanie Quintana; Mamatha Pasnoor; Mazen Dimachkie; Laura Herbelin; Richard Barohn
Journal:  Stat Med       Date:  2015-01-07       Impact factor: 2.373

2.  Are head-to-head trials of biologics needed? The role of value of information methods in arthritis research.

Authors:  Nicky J Welton; Jason Madan; Anthony E Ades
Journal:  Rheumatology (Oxford)       Date:  2011-09       Impact factor: 7.580

3.  Commentary on Hey and Kimmelman.

Authors:  Edward L Korn; Boris Freidlin
Journal:  Clin Trials       Date:  2015-02-03       Impact factor: 2.486

4.  Commentary on Hey and Kimmelman.

Authors:  Steven Joffe; Susan S Ellenberg
Journal:  Clin Trials       Date:  2015-02-03       Impact factor: 2.486

5.  Bayesian approaches for comparative effectiveness research.

Authors:  Donald A Berry
Journal:  Clin Trials       Date:  2011-08-30       Impact factor: 2.486

6.  Commentary on Hey and Kimmelman.

Authors:  J Jack Lee
Journal:  Clin Trials       Date:  2015-02-03       Impact factor: 2.486

7.  Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease.

Authors:  Andrew Satlin; Jinping Wang; Veronika Logovinsky; Scott Berry; Chad Swanson; Shobha Dhadda; Donald A Berry
Journal:  Alzheimers Dement (N Y)       Date:  2016-02-04

8.  Proteus: Mythology to modern times.

Authors:  Senthy V Sellaturay; Raj Nair; Ian K Dickinson; Seshadri Sriprasad
Journal:  Indian J Urol       Date:  2012-10

9.  Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study.

Authors:  Jason T Connor; Bryan R Luce; Kristine R Broglio; K Jack Ishak; C Daniel Mullins; David J Vanness; Rachael Fleurence; Elijah Saunders; Barry R Davis
Journal:  Clin Trials       Date:  2013-08-27       Impact factor: 2.486

10.  A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.

Authors:  Alexandra R Brown; Byron J Gajewski; Lauren S Aaronson; Dinesh Pal Mudaranthakam; Suzanne L Hunt; Scott M Berry; Melanie Quintana; Mamatha Pasnoor; Mazen M Dimachkie; Omar Jawdat; Laura Herbelin; Richard J Barohn
Journal:  Trials       Date:  2016-08-31       Impact factor: 2.279

View more
  1 in total

Review 1.  Challenges, opportunities, and innovative statistical designs for precision oncology trials.

Authors:  Jun Yin; Shihao Shen; Qian Shi
Journal:  Ann Transl Med       Date:  2022-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.